Rasi Electrodes (531233)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 12.18 is modest, assuming current earnings are sustainable.
• Piotroski F-score of 6/9 indicates reasonable financial health for a small-cap.
• Latest quarter shows positive net profit of ₹1 crore on ₹17 crore sales, suggesting operational improvement.
• Stock near 52-week high reflects market anticipation of a recovery.

Concerns

• Sales growth is negative at -10.76%, indicating a shrinking top line.
• Profit growth of 335% is likely from a low base and not repeatable.
• No dividend yield, so shareholders get no cash return.
• Debt/Equity is undisclosed, making leverage and financial risk impossible to assess.
• P/B of 2.41 implies paying a significant premium over book value for a declining business.

AI Analysis

At surface, Rasi Electrodes looks like a classic value trap. The stock trades at ₹28.59, near its 52-week high, with a market cap of just ₹90 crore. The P/E of 12.18 appears reasonable until you inspect the underlying numbers. Sales are shrinking by 10.76% - the business is contracting. Profits jumped 335%, but that percentage is deceptive; it likely comes from a minuscule base. The latest quarter tells the real story: ₹17 crore sales, ₹1 crore net profit - a thin 5.9% margin. Return on equity of 9.94% and ROCE of 10.85% are mediocre. A wonderful business compounds capital at 20% plus with an economic moat; this has no discernible moat. Piotroski F-score of 6/9 offers some comfort, but there is no dividend—management isn't returning cash—and debt/equity is unlisted. As Graham said, you cannot value what you cannot measure. The PEG of 0.04 is mathematically absurd; it relies on that 335% profit growth repeating, which is improbable. Book value stands at ₹11.88, so paying ₹28.59 means a 2.41 times premium. The stock is at the top of its 52-week range (₹9.27-₹28.59), having tripled already. The easy money has likely been made. Without stable sales growth, sustainable margins, or a clearer capital structure, this remains a speculative punt, not an investment. I'd need to see evidence of a genuine turnaround before committing. In the words of Buffett, 'It's better to be unsure than wrong.'

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer